Anavex Life Sciences Corp (AVXL)

[blu_1]

“2-73 has already demonstrated early positive data in AD, and Anavex has demonstrated potential utility in multiple other preclinical models of CNS diseases, including MS. Thus, we see Biogen coming on board, even for early stage studies, as further validating. In addition, what we’ve been learning from CNS-based studies, whether AD or MS, is that the data are complex across multiple endpoints. As such, having the KEM system with Ariana in place to help analyze complex data is, in our view, a strategic positive for Anavex,” Kolbert concludes.